1. Home
  2. REGN vs CVNA Comparison

REGN vs CVNA Comparison

Compare REGN & CVNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • CVNA
  • Stock Information
  • Founded
  • REGN 1988
  • CVNA 2012
  • Country
  • REGN United States
  • CVNA United States
  • Employees
  • REGN N/A
  • CVNA N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • CVNA Other Specialty Stores
  • Sector
  • REGN Health Care
  • CVNA Consumer Discretionary
  • Exchange
  • REGN Nasdaq
  • CVNA Nasdaq
  • Market Cap
  • REGN 59.5B
  • CVNA 47.7B
  • IPO Year
  • REGN 1991
  • CVNA 2017
  • Fundamental
  • Price
  • REGN $568.20
  • CVNA $354.24
  • Analyst Decision
  • REGN Buy
  • CVNA Buy
  • Analyst Count
  • REGN 23
  • CVNA 19
  • Target Price
  • REGN $794.83
  • CVNA $381.53
  • AVG Volume (30 Days)
  • REGN 991.3K
  • CVNA 2.4M
  • Earning Date
  • REGN 10-30-2025
  • CVNA 10-29-2025
  • Dividend Yield
  • REGN 0.62%
  • CVNA N/A
  • EPS Growth
  • REGN 5.03
  • CVNA 104.97
  • EPS
  • REGN 39.67
  • CVNA 4.02
  • Revenue
  • REGN $14,214,200,000.00
  • CVNA $16,274,000,000.00
  • Revenue This Year
  • REGN N/A
  • CVNA $40.20
  • Revenue Next Year
  • REGN $4.97
  • CVNA $25.94
  • P/E Ratio
  • REGN $14.32
  • CVNA $88.22
  • Revenue Growth
  • REGN 5.38
  • CVNA 39.48
  • 52 Week Low
  • REGN $476.49
  • CVNA $126.59
  • 52 Week High
  • REGN $1,170.58
  • CVNA $413.34
  • Technical
  • Relative Strength Index (RSI)
  • REGN 50.07
  • CVNA 47.17
  • Support Level
  • REGN $552.98
  • CVNA $356.48
  • Resistance Level
  • REGN $588.70
  • CVNA $381.89
  • Average True Range (ATR)
  • REGN 16.19
  • CVNA 14.28
  • MACD
  • REGN -3.04
  • CVNA -1.08
  • Stochastic Oscillator
  • REGN 26.70
  • CVNA 38.92

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About CVNA Carvana Co.

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.

Share on Social Networks: